The invention relates oral phamiaceuticai compositions for the modifiedrelease delivery of cariprazine (trans-N-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl} -N',N'-dimethylurea) or pharmaceutically acceptable salts thereof for lessthan daily dosing. The invention also relates to the use of said compositionsin the treatment and/or prevention of pathological conditionswhich require the modulation of dopamine receptors. The invention also relatesto the process for the preparation of said modifiedrelease pharmaceutical compositions.